Bisphosphonates as anticancer therapy for early breast cancer

Clinical Breast Cancer

Volumn 10, Issue 5, 2010, Pages 359-366

  Mahtani, Reshma ^a   Jahanzeb, Mohammad ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Antiangiogenesis; Apoptosis; Immunomodulatory; Zoledronic acid

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BOSUTINIB; CAPECITABINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DASATINIB; DENOSUMAB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEFITINIB; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; SARACATINIB; TAMOXIFEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE ATROPHY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG SAFETY; EARLY CANCER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; INNATE IMMUNITY; JAW OSTEONECROSIS; MULTIPLE MYELOMA; MYELOMA; NONHUMAN; OVERALL SURVIVAL; PATIENT COMPLIANCE; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; TUMOR IMMUNITY;

EID: 77957810248     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.047     Document Type: Review

References (90)

1. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165:1262-4.
2. Masarachia P, Weinreb M, Balena R, et al. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996; 19:281-90.
3. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19:18-54.
4. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10:1478-87.
5. Rogers MJ, Brown RJ, Hodkin V, et al. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Com-mun 1996; 224:863-9.
6. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9:2643-58.
7. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13:581-9.
8. van Beek E, Pieterman E, Cohen L, et al. Farnesyl pyrophosphate synthase is the mo-lecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999; 264:108-11.
9. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranyl-geraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 96:133-8.
10. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4:30-4.
11. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibi-tion of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296:235-42.
12. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Data-base Syst Rev 2005; CD003474.
13. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88:1082-90.
14. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal com-plications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21.
15. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14:1399-405.
16. Avilés A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007; 24:227-30.
17. Hei Y, Lipton A, Shirina N, et al. Effect of zoledronic acid (Zol) compared with pamidronate (Pam) on disease progression in breast cancer (BC) patients with bone metastases stratified by baseline characteristics. J Clin Oncol 2006; 24(18 suppl.):47s (abstract 678).
18. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with meta-static bone disease from lung cancer and elevated markers of osteoclast activity J Thorac Oncol 2008; 3:228-36.
19. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98:962-9.
20. Mystakidou K, Katsouda E, Parpa E, et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22:195-201.
21. Zaghloul MS, Boutrus R, El-Hosieny H, et al. A controlled prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients. J Clin Oncol 2008; 26(15 suppl):257s (abstract 5033).
22. Eidtmann H, Bundred N, deBoer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiv-ing letrozole: 36 months follow-up of ZO-FAST Cancer Res 2009; 69(suppl 2):74s-5s (abstract 44).
23. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 36 0:679-91.
24. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-93.
25. Shipman CM, Rogers MJ, Apperley JF, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98:665-72.
26. Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82:1459-68.
27. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15:2211-21.
28. Coxon JP, Oades GM, Kirby RS, et al. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenyl-ation. BJU Int 2004; 94:164-70.
29. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60:2949-54.
30. Denoyelle C, Hong L, Vannier JP, et al. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and-independent effects. Br J Cancer 2003; 88:1631-40.
31. Meunier PJ, Chapuy MC, Alexandre C, et al. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet 1979; 2:489-92.
32. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62:6538-44.
33. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302:1055-61.
34. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55:3551-7.
35. Mundy GR, Yoneda T, Hiraga T Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001; 28(suppl 6):35-44.
36. Michigami T, Hiraga T, Williams PJ, et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002; 75:249-58.
37. Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10:4559-67.
38. Daubine F, Le Gall C, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007; 99:322-30.
39. Ullen A, Lennartsson L, Harmenberg U, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005; 44:644-50.
40. Brunsvig PF, Andersen A, Aamdal S, et al. Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy. BMC Cancer 2007; 7:197.
41. Melisi D, Caputo R, Damiano V, et al. Zoledronic acid cooperates with a cyclooxy-genase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 2005; 12:1051-8.
42. Vogt U, Bielawski KP, Bosse U, et al. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/methotrexate/5-fluorouracil, epirubicin/cyclo-phosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004; 12:1109-14.
43. Ottewell PD, Monkkonen H, Jones M, et al. Antitumor effects of doxorubicin fol-lowed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008; 100:1167-78.
44. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16:593-602.
45. Massaia M, Attisano C, Peola S, et al. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood 1993; 82:1787-97.
46. Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gamma delta T cells by amino-bisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96:384-92.
47. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects of gamma delta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy Int J Cancer 2005; 116:94-9.
48. Yuasa T, Sato K, Ashihara E, et al. Intravesical administration of gamma delta T cells suc-cessfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 2009; 58:493-502
49. Fiore F, Castella B, Nuschak B, et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007; 110:921-7.
50. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulat-ing angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8:1080-4.
51. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9:2893-7.
52. Santini D, Martini F, Fratto ME, et al. In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009; 58:31-8.
53. Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study Cancer Immunol Immunother 2007; 56:469-76.
54. Psaila B, Kaplan RN, Port ER, et al. Priming the "soil" for breast cancer metastasis: the premetastatic niche. Breast Dis 2006-2007; 26:65-74.
55. Shiozawa Y, Havens AM, Pienta KJ, et al. The bone marrow niche: habitat to he-matopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008; 22:941-50.
56. Tarin D. New insights into the pathogenesis of breast cancer metastasis. Breast Dis 2006-2007; 26:13-25.
57. Bidard FC, Vincent-Salomon A, Gomme S, et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008; 14:3306-11.
58. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353:793-802. (Pubitemid 41215488)
59. Aft R, Naughton M, Ylagan L, et al. Effect of zoledronic acid on bone marrow micro-metastases in women undergoing neoadjuvant chemotherapy for breast cancer [poster]. Presented at: the 44th Annual Meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL. Abstract 1021.
60. Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow [poster]. Presented at: the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 510.
61. Rack BK, Jueckstock J, Genss E-M, et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer [poster]. Presented at: the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 511.
62. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [poster]. Presented at: the 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 2048.
63. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006; 8:R13.
64. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-63.
65. Jaschke A, Bastert G, Solomayer EF, et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow-a longtime follow-up. J Clin Oncol 2004; 22(14 suppl):9 (abstract 529).
66. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow a long-term follow-up. Ann Oncol 2008; 19:2007-11.
67. Saarto T, Vehmanen L, Virkkunen P, et al. Ten-year follow-up of a randomized con-trolled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004; 43:650-6.
68. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007; 96:1796-801.
69. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335:1785-91.
70. Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006; 106:2337-44.
71. Frassoldati A, Brufsky A, Bundred N, et al. The effect of zoledronic acid on aroma-tase inhibitor (AI) associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months (mos) integrated follow-up of the Z-FAST/ZO-FAST trials. Ann Oncol 2008; 19(suppl 8):viii78 (abstract 185PD).
72. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST Study 36-month follow-up results. Clin Breast Cancer 2009; 9:77-85.
73. Winter MC, Thorpe HC, Burkinshaw R, et al. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response-exploratory evidence for direct anti-tumor activity in breast cancer [poster]. Presented at the 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX Abstract 5101.
74. Reimer T, Nitz U, Potenberg J, et al. ICE Study: Ibandronate with or without capecitabine in elderly patients with early breast cancer. Breast 2009; 18(suppl 1):S58 (abstract 0155).
75. von Minckwitz G, Mobus V, Conrad B, et al. GAIN Study: a phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node positive primary breast cancer. Breast 2009; 18(suppl 1):S59 (abstract 0157).
76. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420-32.
77. Llombart A. Zoledronic acid in the prevention of aromatase inhibitor-associated bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (E-ZO-FAST Trial) [poster]. Presented at: the European Cancer Conference 14; Barcelona, Spain; September 23-27, 2007. Abstract 2.044.
78. Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study [oral presentation]. Presented at: the European Cancer Conference 15-34th European Society for Medical Oncology Multidisciplinary Congress; Berlin, Germany; September 20-24, 2009. Abstract 2LBA.
79. Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma [oral presentation]. Presented at: the European Cancer Conference 15-34th European Society for Medical Oncology Multidisciplinary Congress; Berlin, Germany; September 20-24, 2009. Abstract 20LBA
80. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23:826-36.
81. Estilo CL, Van Poznak CH, Wiliams T, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy Oncologist 2008; 13:911-20.
82. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecro-sis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20:137-45.
83. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479-91.
84. Weitzman R, Sauter N, Eriksen EF, et al. Critical review: updated recommenda-tions for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 2007; 62:148-52.
85. Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008; 13:503-14.
86. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26:4875-82.
87. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010; 36:177-84.
88. Pichot CS, Hartig SM, Xia L, et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 2009; 101:38-47.
89. Yu EY, Wilding G, Posadas E, et al. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. J Clin Oncol 2008; 26(15 suppl):288s (abstract 5156).
90. Hannon RA, Clack G, Rimmer M, et al. Effects of the Src kinase inhibitor saraca-tinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial. J Bone Miner Res 2010; 25:463-71.